Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000068-40
    Sponsor's Protocol Code Number:FAIR-HF2
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-09-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2016-000068-40
    A.3Full title of the trial
    Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality.
    Ferric carboxymaltose Assessment of morbidity and mortality in patients with IRon deficiency and chronic Heart Failure – FAIR–HF2
    Intravenöses Eisen bei Patienten mit systolischer Herzinsuffizienz
    und Eisenmangel zur Verbesserung der Morbidität und Mortalität
    (Eisencarboxymaltose Bewertung der Morbidität und Mortalität bei
    Patienten mit Eisen-Mangel und chronischer Herzinsuffizienz)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to investigate the improvement on morbitity and mortality and frequence of disease by intravenous iron therapy in patients with disturbance of heart function and iron deficiency
    Untersuchung zur Verbesserung der Krankheitshäufigkeit und Sterblichkeit von Patienten mit Störung der Herzpumpfunktion und Eisenmangel durch eine intravenöse Eisentherapie
    A.4.1Sponsor's protocol code numberFAIR-HF2
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversity Medical Center Hamburg-Eppendorf
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDeutsches Zentum für Herz-Kreislauf-Forschung
    B.4.2CountryGermany
    B.4.1Name of organisation providing supportVifor Pharma
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversity Medical Center Hamburg-Eppendorf
    B.5.2Functional name of contact pointMahir Karakas
    B.5.3 Address:
    B.5.3.1Street AddressMartinistrasse 52
    B.5.3.2Town/ cityHamburg
    B.5.3.3Post code20246
    B.5.3.4CountryGermany
    B.5.4Telephone number004940741057975
    B.5.5Fax number004940741055619
    B.5.6E-mailm.karakas@uke.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ferinject
    D.2.1.1.2Name of the Marketing Authorisation holderVifor France SA
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFERRIC CARBOXYMALTOSE
    D.3.9.1CAS number 9007-72-1
    D.3.9.4EV Substance CodeSUB66620
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection/infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Systolic heart failure associated with iron deficiency
    Systolische Dysfunktion des Herzens in Verbindung mit einem Eisenmangel
    E.1.1.1Medical condition in easily understood language
    Reduces heart's pumping associated with iron deficiency
    Verminderte Pumpfunktion des Herzes in Verbindung mit einem Eisenmangel
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10074631
    E.1.2Term Systolic heart failure
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the FAIR-HF2 trial is to show that treatment of patients with systolic heart failure and iron deficiency with i.v. iron (Ferric Carboxymaltose, FCM) versus placebo (i.v. NaCl) can reduce the rate of recurrent events of heart failure hospitalisations and cardiovascular (CV) death.
    Verringerung der Häufigkeit von erneutem Krankenhausaufenthalt aufgrund von Herzinsuffizienz und kardiovaskulärem Tod durch die i.v. Gabe von Eisencarboxymaltose (FCM) im Vergleich zu Placebo (i.v. NaCl) bei Patienten mit Herzinsuffizienz und Eisenmangel.
    E.2.2Secondary objectives of the trial
    Secondary objectives include the demonstration that in these patients treatment with FCM versus placebo can reduce the time-to-first-event and the rate of recurrent events of heart failure / cardiovascular hospitalisations and CV death, and the respective components of these composite endpoints. An additional aim is to show the cost-effectiveness of the intervention.
    • Nachweis, dass die Behandlung dieser Patienten mit FCM im Vergleich zu Placebo die Zeit bis zum ersten Ereignis und die Rate der wiederkehrenden Krankenhausaufenthalte aufgrund von kardiovaskulären Ereignissen und kardiovaskulärem Tod sowie die jeweiligen Komponenten dieser zusammengesetzten Endpunkteverringern kann.
    • Nachweis der Kosteneffizienz der Behandlung
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Patients with chronic HFrEF (CHF) of at least 3 months duration and a history of documented LVEF<45%.
    2. Confirmed presence of ID (ferritin < 100 ng/mL or ferritin 100 - 299 ng/mL with TSAT < 20 %)
    3. Serum haemoglobin of 9.5 - 14.0 g/dL
    4. At time of screening considered re-stabilised and planned for discharge within next 24 h (NYHA 2 or 3), or stable ambulatory with a HF hospitalisation in the past 12 months (NYHA 2-4), or stable ambulatory with BNP > 100 pg/mL or NT-proBNP > 300 pg/mL or MR-proANP > 120 pmol/L (NYHA 2-4)
    5. Written informed consent
    1. Patienten mit einer chronischen Herzerkrankung (HFrEF) für mindestens 3
    Monate mit dokumentierter LVEF < 45%
    2. Bestätigter Eisenmangel (ferritin < 100 ng/mL or ferritin 100 - 299
    ng/mL with TSAT < 20 %)
    3. Serumhämoglobin zwischen 9.5 und 14.0 g/dL
    4. Zum Zeitpunkt des Screenings vermuteter stabiler Zustand des
    stationären Patienten und geplante Entlassung innerhalb von 24h (NYHA 2 oder 3), oder
    stabiler ambulanter Patient mit Hospitalisierung aufgrund einer
    Herzerkrankung in den letzten 12 Monaten (NYHA 2-4) oder stabiler ambulanter
    Patient mit BNP > 100 pg/mL or NT-proBNP > 300 pg/mL or MR-proANP
    > 120 pmol/L (NYHA 2-4)
    5. Schriftliche Einwilligungserklärung
    E.4Principal exclusion criteria
    1. Hypersensitivity to the active substance, to FCM or any of its excipients
    2. Known serious hypersensitivity to other parenteral iron products
    3. Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia
    4. Evidence of iron overload or disturbances in the utilisation of iron
    5. History of severe asthma with known FEV1 <50%
    6. Acute bacterial infection
    7. Presence of a deficiency for vitamin B12 and/or serum folate (if present, this needs to be corrected first)
    8. Use of renal replacement therapy
    9. Treatment with an erythropoietin stimulating agent (ESA), any i.v. iron and/or a blood transfusion in the previous 6 weeks prior to randomisation.
    10. More than 500 meters in the initial 6-minutes walking-test
    Note:
    - We aim to recruit at least half of the patients with an initial 6-minute walking-test below 375 meters
    - We aim to recruit >80% of the patients with a TSAT <20%
    - We aim to recruit >75% of the patients with ischemic cardiomyopathy
    1. Überempfindlichkeit gegen einen Bestandteil der Prüfmedikation
    2. Bekannte Überempfindlichkeit gegen ein anders parenteral zu
    verabreichendes Eisenpräparat
    3. Anämie, die nicht aufgrund eines Eisenmangels besteht
    4. Verdacht auf Eisenüberladung
    5. In der Krankengeschichte Schwerem Asthma mit FEV1 <50%
    6. Akuter bakterieller Infekt
    7. Vitamin 12-/Folat-Mangel
    8. Renale Ersatztherapie
    9. Behandlung mit einem ESA, jedweden i.v. Eisenpräparaten, und/oder
    einer Bluttransfusion 6 Wochen vor Randomisierung.
    10. Mehr als 500 Meter beim initialen 6-Minuten-Gehtest
    Hinweise:
    - Wir streben an, mindestens die Hälfte der Patienten mit einem anfänglichen 6-Minuten-Gehtest unter 375 Metern zu rekrutieren.
    - Wir streben an >80% der Patienten mit einer TSAT <20% rekrutieren
    - Wir streben an >75 % der Patienten mit ischämischer Kardiomyopathie zu rekrutieren
    E.5 End points
    E.5.1Primary end point(s)
    Rate of total (first and recurrent) events of hospitalisations for heart failure and of CV death.
    Rate der gesamten (erster und wiederkehrender) Hospitalisierungen aufgrund von Herzinsuffizienz und kardiovaskulären Todesfällen.
    E.5.1.1Timepoint(s) of evaluation of this end point
    During follow-up
    Während Follow-up
    E.5.2Secondary end point(s)
    • Time-to-first event of CV death or HF hospitalization
    • Rate of total (first and recurrent) HF hospitalisations
    • Combined rate of total (first and recurrent) CV hospitalisations and of CV death
    • Rate of total (first and recurrent) CV hospitalisations
    • CV mortality
    • All-cause mortality
    • Rate of total (first and recurrent) hospitalisations of any kind
    • Combined rate of total (first and recurrent) hospitalisations for any reason and all-cause mortality
    • Changes in 6-minute walk-test, NYHA functional class, EQ-5D, and PGA of wellbeing during follow-up (from baseline to various time-points of follow-up)
    • Exploratory: Changes in renal, cardiovascular, inflammatory and metabolic parameters during follow-up (from baseline to various time-points of follow-up)

    Further analyses:
    For the primary clinical efficacy endpoint, as well as other important clinical endpoints – especially recurrent heart failure hospitalisations, recurrent CV hospitalisations; CV death, all-cause-death, and combinations thereof - a meta-analysis with all other relevant controlled clinical trials testing ferric carboxymaltose and/ or other iv iron formulations (e.g. FAIR-HF, AFFIRM-AHF, CONFIRM-HF, IRON-MAN, HEART-FID) will be performed:
    (i) only trials using FCM
    (ii) all trials using any iv iron formulations
    • Zeit bis zum ersten Ereignis eines kardiovaskulären Todesfalls oder einer Hospitalisierung aufgrund von Herzinsuffizienz
    • Rate der gesamten (ersten und wiederkehrenden) Hospitalisierungen aufgrund von Herzinsuffizienz
    • Kombinierte Rate der gesamten (erster und wiederkehrender) Hospitalisierungen aufgrund von kardiovaskulären Ereignissen und kardiovaskulären Todesfällen
    • Rate der gesamten (erster und wiederkehrender) Hospitalisierungen aufgrund von kardiovaskulären Ereignissen
    • Kardiovaskuläre Todesfälle
    • Todesfälle jeglicher Ursachen
    • Rate der gesamten (erster und wiederkehrender) Hospitalisierungen aufgrund anderer Ursachen
    • Kombinierte Rate der gesamten (erster und wiederkehrender) Hospitalisierungen auf Grund anderer Ursachen und kardiovaskulären Todesfällen
    • Änderungen im 6-Minuten-Gehtest, der NYHA Funktionsklasse, EQ-5D und PGA Wohlbefinden während der Follow-up Phase (von Baseline bis zu verschiedenen Zeitpunkten der Follow-up Phase)
    • Erforschend: Änderungen von renalen, kardiovaskulären, entzündlichen und metabolischen Parametern während des Follow-Ups (von baseline bis zu verschiedenen Zeitpunkten der Follow-up Phase)
    Weitere Analysen:
    Für den primären klinischen Wirksamkeitsendpunkt sowie für andere wichtige klinische Endpunkte - insbesondere rezidivierende Herzinsuffizienz-Krankenhausaufenthalte, rezidivierende CV-Krankenhausaufenthalte; CV-Tod, Todesfälle jeglicher Ursachen und Kombinationen davon - wird eine Metaanalyse mit allen anderen relevanten kontrollierten klinischen Studien durchgeführt, in denen Eisen(III)-Carboxymaltose und/oder andere iv-Eisen-Formeln im Vergleich zu Placebo (z.B. FAIR-HF, AFFIRM-AHF, CONFIRM-HF, IRONMAN, HEART-FID) getestet werden:
    (i) nur Studien, die FCM verwenden
    (ii) alle Versuche, bei denen eine beliebige Eisenformulierung verwendet wurde
    E.5.2.1Timepoint(s) of evaluation of this end point
    We aim for a minimum average follow-up of >2 years. We aim for a minimum follow-up of 6 months for all patients, but not less than 3 months.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned17
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA61
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Serbia
    Hungary
    Italy
    Poland
    Portugal
    Slovenia
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 165
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 335
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state600
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1000
    F.4.2.2In the whole clinical trial 1200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Keine
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-09-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-27
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 02:34:15 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA